Kura Oncology, Inc.
KURA
$7.58
-$0.07-0.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.36% | -73.82% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.36% | -73.82% | |||
| Cost of Revenue | 12.17% | -63.97% | |||
| Gross Profit | -13.45% | 58.74% | |||
| SG&A Expenses | 10.22% | -5.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.61% | 3.24% | |||
| Operating Income | -12.31% | -188.13% | |||
| Income Before Tax | -15.59% | -232.59% | |||
| Income Tax Expenses | -- | -88.80% | |||
| Earnings from Continuing Operations | -15.14% | -198.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.14% | -198.84% | |||
| EBIT | -12.31% | -188.13% | |||
| EBITDA | -12.38% | -189.69% | |||
| EPS Basic | -14.90% | -197.96% | |||
| Normalized Basic EPS | -15.35% | -87.96% | |||
| EPS Diluted | -14.90% | -197.96% | |||
| Normalized Diluted EPS | -15.35% | -87.96% | |||
| Average Basic Shares Outstanding | 0.20% | 0.32% | |||
| Average Diluted Shares Outstanding | 0.20% | 0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||